Latest news for Hardcore Discoveries (OTC:MAKAF) Stock

Hardcore Discoveries Ltd formerly Makara Mining Corp is engaged in the business of mineral exploration in Canada. Its projects include Rude Creek Property, Kenora Gold Property, Win Property, Idaho Property, and Davis & Paradise Properties.

HARDCORE DISCOVERIES LTD by Hardcore Discoveries Ltd

Hardcore Discoveries Ltd

News

Dividends

Albertsons Increases Quarterly Dividend From $0.12 To $0.15

Vera Bradley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>) reported its Q3 earnings results on Wednesday, December 11, 2024 at 08:00 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Vera Bradley missed estimated earnings by -550.0%, reporting an EPS of $-0.27 versus an estimate of $0.06.
Revenue was down $34.41 million from the same period last year.
<h3>Earnings History Overview</h3>
Last quarter the company missed on EPS by $0.03 which was followed by a 4.0% increase in the share price the next day.
Here's a look at Vera Bradley's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.16</td>
<td>0</td>
<td>0.14</td>
<td>0.09</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.13</td>
<td>-0.21</td>
<td>0.11</td>
<td>0.19</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>120.66M</td>
<td>90.39M</td>
<td>136.05M</td>
<td>123.09M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>110.82M</td>
<td>80.60M</td>
<td>133.26M</td>
<td>114.99M</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Vera Bradley management provided guidance for FY 2025, expecting earnings between $-0.25 and $-0.25 per share.
 Listen to the earnings announcement yourself by <a href="">clicking here</a>. 
To track all earnings releases for Vera Bradley <a href="https://www.benzinga.com/quote/VRA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Recap: Vera Bradley Q3 Earnings

Guidance

MTCH

Match Group Updates Q4 2024 Outlook At Investor Day; Revenue Expected To Fall Below Prior Guidance Due To $15M FX Impact, Two-Thirds Attributable To Tinder; Full-Year Adjusted Operating Income Margin Still On Track At 36%

Buybacks

Albertsons Authorizes $2B Share Repurchase Program

AMPG

AmpliTech Group Announces Development And Deployment Of Its Low-Noise Cryogenic HEMT Amplifiers

Match Group Hosts Inaugural Investor Day, Announces $0.19 Quarterly Dividend And $1.5B Share Buyback Authorization; Plans To Return 100% Of Free Cash Flow To Shareholders Over Three Years Through Dividends And Repurchases

Albertsons Terminates Merger Agreement With Kroger

Biotech

General

ENLV

Enlivex Therapeutics Receives Regulatory Authorization From Israeli Ministry Of Health For Initiation Of Phase I Trial Evaluating Allocetra In Patients With TMJ Osteoarthritis

Refreshed Leadership To Accelerate Product Commercialization And Expand AI And Polymer Material Applications For Growth Opportunities

Management

LWLG

Lightwave Logic Appoints Yves LeMaitre As CEO And Thomas E. Zelibor As President

On Wednesday, Macy&#8217;s Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) reported third-quarter sales of $4.74 billion, beating the <a target="_blank" href="https://www.benzinga.com/trading-ideas/technicals/24/12/42422245/macys-q3-earnings-loom-can-bullish-momentum-break-200-day-resistance" rel="noreferrer noopener">consensus of $4.72 billion</a>.
Macy&#8217;s net sales decreased 2.4%, with comparable sales down 2.4% on an owned basis and down 1.3% on an owned-plus-licensed-<a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42432930/macys-inc-reports-third-quarter-2024-results" rel="noreferrer noopener">plus-marketplace basis</a>.
Sales growth at Macy&#8217;s First 50 locations, Bloomingdale&#8217;s, and Bluemercury was offset primarily by weakness in Macy&#8217;s non-First 50 locations, digital channels, and cold weather categories.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/42162655" rel="noreferrer noopener">Macy&#8217;s Delays Q3 Earnings Report Amid Investigation Over $154M Accounting Scandal; Stock Dips</a>
Macy&#8217;s go-forward business&nbsp;comparable sales were down 2.0% on an owned basis and down 0.9% on an owned-plus-licensed-plus-marketplace basis.
Bloomingdale&#8217;s net sales were up 1.4%, with comparable sales up 1.0% on an owned basis and up 3.2% on an owned-plus-licensed-plus-marketplace basis. Key drivers included strength in contemporary apparel, beauty, and digital.
Bluemercury net sales were up 3.2%, and comparable sales were up 3.3% on an owned basis.
&#8220;Our third quarter results reflect the positive momentum we are building through our Bold New Chapter strategy,&#8221; said Tony Spring, chairman and chief executive officer of Macy&#8217;s.
&#8220;We are encouraged by the consistent sales growth in our Macy&#8217;s First 50 locations and the strong performance of Bloomingdale&#8217;s and Bluemercury. Quarter-to-date, comparable sales continue to trend ahead of third-quarter levels across the portfolio.&#8221;
In November, the department store chain delayed its Q3 earnings release to allow for&nbsp;the completion of an <a target="_blank" href="https://www.benzinga.com/24/11/42162655/macy-falls-as-preliminary-q3-highlights-mixed-performance-and-154-million-expense-concealment" rel="noreferrer noopener">independent investigation</a>.
In its Q3 earnings release, the company said it identified that a single employee with responsibility for small package delivery expense accounting intentionally made erroneous accounting accrual entries to hide approximately $151 million of cumulative delivery expenses from the fourth quarter of 2021 through the third quarter of 2024
The retailer reported adjusted EPS of $0.04, down from $0.21 a year ago, beating the consensus of $0.03.
Guidance: Macy&#8217;s expects 2024 sales of&nbsp;$22.3 billion—$22.5 billion, compared to prior&nbsp;guidance&nbsp;of&nbsp;$22.1 billion—$22.4 billion&nbsp;and a consensus of&nbsp;$22.42 billion.
The company expects a 2024 comparable owned-plus-licensed-plus-marketplace sales change of Down ~1.0% to ~flat versus 2023 versus Down ~2.0% to down ~0.5% expected earlier.
Macy&#8217;s expects 2024 adjusted EPS of&nbsp;$2.25-$2.50&nbsp;compared to prior&nbsp;guidance&nbsp;of&nbsp;$2.34-$2.69&nbsp;and a consensus of&nbsp;$2.73, including accounting error.
Price Action: At last check on Wednesday, M stock was down 10.3% at $14.99 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42177026" target="_blank" rel="noreferrer noopener">Peacock Pays Up: Macy&#8217;s Thanksgiving Parade Costs Set To Balloon For Content-Hungry NBC</a></li>
</ul>
Image via Shutterstock

Movers

Trading Ideas

Macy's Lowers Annual Profit Forecast Amid Accounting Misstep, Stock Tumbles

Wells Fargo analyst Larry Biegelsen downgrades RxSight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) from Overweight to Equal-Weight and lowers the price target from $56 to $42.

Downgrades

Price Target

Analyst Ratings

RXST

Wells Fargo Downgrades RxSight to Equal-Weight, Lowers Price Target to $42

Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea's experimental drug, ATRN-119, over a 24-hour daily cycle
New regimen potentially optimizes clinical outcomes and strengthens the clinical path forward
ATRN-119 is the first macrocyclic ATR inhibitor to enter clinical trials

APRE

Aprea Therapeutics Announces Twice Daily Dosing Of Patients On ABOYA-119 Clinical Trial Of ATRN-119

WIIM

SPWH

Sportsman's Warehouse shares are trading higher after B. Riley Securities upgraded the stock from Neutral to Buy and raised its price target from $2 to $4.

Truist Securities analyst Anthony Hau maintains DigitalBridge Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBRG#NYSE">DBRG</a>) with a Buy and lowers the price target from $17 to $15.

DBRG

Truist Securities Maintains Buy on DigitalBridge Gr, Lowers Price Target to $15

In the current market session, Trimble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMB#NASDAQ">TRMB</a>) stock price is at $74.00, after a 0.16% drop. However, over the past month, the company's stock spiked by 2.08%, and in the past year, by 43.14%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1733923840_0.png" alt="Past Year Chart" />

<h3>Evaluating Trimble P/E in Comparison to Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 44.41 in the Electronic Equipment, Instruments &amp; Components industry, Trimble Inc. has a lower P/E ratio of 12.39. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1733923840_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

TRMB

P/E Ratio Insights for Trimble

SCPH

ScPharmaceuticals shares are trading lower after the company disclosed observed variability during shelf-life testing in one lot of its SCP-111 combination product. This may result in the submission occurring later in 2025.

Macro Economic Events

Econ #s

US Core CPI (YoY) (Nov) +3.3% vs +3.3% Est.; Prior 3.3%

Economics

USA Core CPI (MoM) For November 0.3% Vs 0.3% Est.; 0.3% Prior

USA CPI (MoM) For November 0.3% Vs 0.3% Est.; 0.2% Prior

Truist Securities analyst Anthony Hau maintains Sun Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUI#NYSE">SUI</a>) with a Hold and lowers the price target from $138 to $131.

Truist Securities Maintains Hold on Sun Communities, Lowers Price Target to $131

Hardcore Discoveries

Makara Mining

Comments

Hardcore Discoveries

News

Latest news for Hardcore Discoveries (OTC:MAKAF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga